Poolbeg Pharma on patent grant and plans - ICYMI

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) earlier this week announced that it had secured its first national patent grant covering its POLB-001 programme in cancer immunotherapy-induced cytokine release syndrome (CRS), marking a significant step in the company's expansion into oncology. Chief executive Jeremy Skillington said the patent, granted by IP Australia, covered the use of P38 MAPK inhibitors, including POLB-001, for preventing CRS linked to cancer immunotherapy.